A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.
Public ClinicalTrials.gov record NCT01783444. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Three-arm, Randomized, Open Label, Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a three-arm, randomized, open label, multi-center phase II study investigating the combination of everolimus (10mg daily) with exemestane (25mg daily) versus everolimus (10mg daily) versus capecitabine (1250mg/m2 twice daily for 14 days, 3-week cycle) in patients with estrogen-receptor positive, HER2 negative, advanced breast cancer after recurrence or progression on letrozole or anastrozole.
Study identification
- NCT ID
- NCT01783444
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 309 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2013 (Actual)
- Primary completion
- Jul 2, 2018 (Actual)
- Completion
- Jul 30, 2018 (Actual)
- Last update posted
- Feb 26, 2021
2013 – 2018
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California at Los Angeles Mattel Children's Hospital | Los Angeles | California | 90095 | — |
| Sharp Memorial Hospital SharpClinicalOncologyResearch | San Diego | California | 92123 | — |
| Florida Cancer Specialists Dept of Oncology (2) | Fort Myers | Florida | 33901 | — |
| Florida Cancer Specialists FL Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Lahey Clinic Dept of Lahey Clinic (2) | Burlington | Massachusetts | 01805 | — |
| New England Hematology/ Oncology Associates, P.C. SC | Newton | Massachusetts | 02462 | — |
| Glacier View Research Institute - Cancer SC | Kalispell | Montana | 59901 | — |
| Trinitas Comprehensive Cancer Center SC | Elizabeth | New Jersey | 07207 | — |
| Hackensack University Medical Center Dept of Oncology | Hackensack | New Jersey | 07601 | — |
| Rutgers-New Jersey Medical School SC | Newark | New Jersey | 07101 | — |
| Oncology Hematology Care Inc Oncology Hematology Care 2 | Cincinnati | Ohio | 45242 | — |
| Oklahoma Cancer Specialists and Research Institute Oklahoma Cancer Specialists | Tulsa | Oklahoma | 74136 | — |
| Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology | Chattanooga | Tennessee | 37404 | — |
| The Jones Clinic SC | Germantown | Tennessee | 38138 | — |
| University of Tennessee SC | Knoxville | Tennessee | 27920-6969 | — |
| Sarah Cannon Research Institute SC (2) | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD | Fort Worth | Texas | 76104 | — |
| University of Virginia Health Systems SC-4 | Charlottesville | Virginia | 22908-0334 | — |
| Northwest Medical Specialties Dept of Onc | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01783444, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 26, 2021 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01783444 live on ClinicalTrials.gov.